Stammdaten
Gilead Sciences, Inc., ein Biopharmaunternehmen, entdeckt, entwickelt und vermarktet Arzneimittel in Bereichen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten, Europa und international. Das Unternehmen bietet Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild und Atripla zur Behandlung von HIV/AIDS; Veklury, ein Injektionspräparat zur intravenösen Anwendung zur Behandlung der Coronavirus-Krankheit 2019; und Epclusa, Harvoni, Vosevi, Vemlidy und Viread zur Behandlung von Lebererkrankungen. Es bietet auch Yescarta, Tecartus, Trodelvy und Zydelig zur Behandlung von Hämatologie-, Onkologie- und Zelltherapiepatienten. Darüber hinaus bietet das Unternehmen Letairis, ein Mundpräparat zur Behandlung der pulmonalen arteriellen Hypertonie; Ranexa, ein Mundpräparat zur Behandlung von chronischer Angina; und AmBisome, eine liposomale Formulierung zur Behandlung schwerwiegender invasiver Pilzinfektionen. Gilead Sciences, Inc. hat Kooperationsvereinbarungen mit Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; und Merck & Co, Inc. Das Unternehmen wurde 1987 gegründet und hat seinen Hauptsitz in Foster City, Kalifornien. KI
Unternehmen & Branche
| Name | GILEAD SCIENCES, INC. |
|---|---|
| Ticker | GILD |
| CIK | 0000882095 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Pharmazeutische Erzeugnisse |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 375558103 |
|---|---|
| ISIN | US3755581036 |
| Typ | Common Stock |
| Marktkapitalisierung | 160,47 Mrd. USD |
| KGV (P/E) | 19,07 |
| Beta | 0,32 |
| Dividendenrendite | 0,02 % |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 333 LAKESIDE DR, 94404 FOSTER CITY, CA |
| Telefon | 6505743000 |
| EIN (IRS) | 94-3047598 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | GILEAD SCIENCES INC (bis 2022) |
Bewertung
| KBV (P/B) | 7,07 vs. 4,32 (2021) ▲ |
|---|---|
| KUV (P/S) | 5,45 vs. 3,33 (2021) ▲ |
| FCF-Rendite | 5,9 % vs. 11,9 % (2021) ▼ |
| Buyback-Rendite | 1,2 % vs. 0,6 % (2021) ▲ |
| Ausschüttungsquote | 47,0 % vs. 57,9 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 78,8 % vs. 75,8 % (2021) ▲ |
|---|---|
| Operative Marge | 34,0 % vs. 36,3 % (2021) ▼ |
| Nettomarge | 28,9 % vs. 22,8 % (2021) ▲ |
| ROIC | 17,6 % vs. 12,9 % (2021) ▲ |
| Zinsdeckungsgrad | 9,8 vs. 9,9 (2021) ▼ |
| Forderungslaufzeit (DSO) | 61 T vs. 60 T (2021) ▲ |
| Lagerreichweite (DIO) | 104 T vs. 89 T (2021) ▲ |
| Verbindlichkeitslaufzeit (DPO) | 42 T vs. 39 T (2021) ▲ |
| Cash-Conversion-Cycle (CCC) | 123 T vs. 111 T (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 4,32 | 5,04 | 4,42 | 5,95 | 6,71 | 6,82 | |
| KUV (P/S) | 3,33 | 3,92 | 3,72 | 4,00 | 5,17 | 5,40 | |
| EV/EBITDA | 9,5 | 13,5 | – | – | – | – | |
| FCF-Rendite | 11,9 % | 7,8 % | 7,4 % | 9,0 % | 6,2 % | 6,4 % | |
| Buyback-Rendite | 0,6 % | 1,3 % | 1,0 % | 1,0 % | 1,3 % | 1,0 % | |
| Ausschüttungsquote | 57,9 % | 80,8 % | 67,2 % | 816,3 % | 47,0 % | 43,8 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 75,8 % | 79,3 % | 76,0 % | 78,3 % | 78,8 % | 79,4 % | |
| Operative Marge | 36,3 % | 26,9 % | 28,0 % | 5,8 % | 34,0 % | 34,9 % | |
| Nettomarge | 22,8 % | 16,8 % | 20,9 % | 1,7 % | 28,9 % | 31,0 % | |
| ROIC | 12,9 % | 9,8 % | 11,7 % | 1,0 % | 17,6 % | 20,2 % | |
| Nettoverschuldung/EBITDA | 1,8 | 2,2 | – | – | – | – | |
| Zinsdeckungsgrad | 9,9 | 7,8 | 8,1 | 1,7 | 9,8 | 10,3 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
GILD
GILEAD SCIENCES, INC.
ⓘ
Eingeschränkte Aussagekraft — erst 64 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv
Stark
Handelsvolumen
Sehr hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
70,4
237 neu, 840 erhöht, 6033,3M $ netto
Aktivist
51,2
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 129.60 | +0.7 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 131.48 | -0.7 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 17 Tagen @ 125.97 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 130.78 | EMA50: 130.83 | |
| MACD-Histogramm | Bärisch | 10 % | -0.296 | Bearisch | |
| RSI(14) | Neutral | 10 % | 49.9 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 22.4 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 14.9 | +DI: 25.3 / −DI: 21.3 | |
| Z-Score(60) | Neutral | 5 % | 0.09 | In Range | |
| 52W-Position | Neutral | 5 % | 44.5 % | Hoch 155.80 / Tief 110.28 | |
| Bollinger(20,2σ) | Neutral | 5 % | 44.2 % | Upper 137.35 / Mid 131.23 / Lower 125.11 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0379 | R²=0.03 / annualisiert -7.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 129,93 | -389.776,80 | -32,5% | |
| 2026-07-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3.000 | 129,92 | -389.757,60 | -32,5% | |
| 2026-07-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.100 | 127,08 | -393.932,50 | -32,9% | |
| 2026-07-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -11.900 | 126,09 | -1.500.467,43 | -125,3% | |
| 2026-06-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -450 | 125,40 | -56.430,00 | -4,7% | |
| 2026-06-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -1.480 | 123,42 | -182.656,57 | -15,2% | |
| 2026-06-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -1.070 | 124,00 | -132.675,51 | -11,1% | |
| 2026-06-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 125,40 | -376.200,00 | -31,4% | |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.062 | 132,22 | -404.842,64 | -33,8% | |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.900 | 131,10 | -1.428.983,46 | -119,3% | |
| 2026-06-01 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1.038 | 132,97 | -138.020,58 | -11,5% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -700 | 132,75 | -92.925,98 | -7,8% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -11.177 | 131,19 | -1.466.329,63 | -122,4% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -8.374 | 132,23 | -1.107.314,12 | -92,4% | |
| 2026-05-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -7.749 | 130,29 | -1.009.628,83 | -84,3% | |
| 2026-05-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 132,27 | -396.810,00 | -33,1% | |
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.950 | 128,79 | -895.074,52 | -74,7% | |
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.050 | 130,01 | -396.533,86 | -33,1% | |
| 2026-04-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3.000 | 140,96 | -422.880,00 | -35,3% | |
| 2026-04-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 140,96 | -422.880,00 | -35,3% | |
| 2026-03-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 136,82 | -1.368.162,00 | -114,2% | |
| 2026-03-16 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3.000 | 144,23 | -432.690,00 | -36,1% | |
| 2026-03-16 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 144,23 | -432.690,00 | -36,1% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.481 | 144,04 | -501.386,18 | -41,9% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.419 | 145,18 | -931.901,43 | -77,8% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -100 | 145,71 | -14.571,00 | -1,2% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -200 | 155,62 | -31.124,00 | -2,6% | |
| 2026-02-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 154,43 | -463.290,00 | -38,7% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -18.405 | 154,18 | -2.837.719,71 | -236,9% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -9.395 | 154,91 | -1.455.384,15 | -121,5% | |
| 2026-02-05 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115.640 | 150,00 | -17.346.000,00 | -1448,1% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -4.968 | 140,24 | -696.725,24 | -58,2% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -5.032 | 139,54 | -702.185,91 | -58,6% | |
| 2026-01-23 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115.640 | 135,00 | -15.611.400,00 | -1303,3% | |
| 2026-01-20 | Bluestone Jeffrey | Director | Open Market Sale | -5.000 | 123,50 | -617.500,00 | -51,6% | |
| 2026-01-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 124,31 | -372.930,00 | -31,1% | |
| 2026-01-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 124,31 | -372.930,00 | -31,1% | |
| 2025-12-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 124,83 | -1.248.272,00 | -104,2% | |
| 2025-12-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 122,00 | -366.000,00 | -30,6% | |
| 2025-12-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3.000 | 122,00 | -366.000,00 | -30,6% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6.788 | 126,84 | -861.015,71 | -71,9% | |
| 2025-11-28 | Kramer Kelly A. | Director | Open Market Sale | -2.805 | 127,10 | -356.515,50 | -29,8% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3.212 | 125,91 | -404.428,06 | -33,8% | |
| 2025-11-28 | Bluestone Jeffrey | Director | Open Market Sale | -5.000 | 125,08 | -625.400,00 | -52,2% | |
| 2025-11-26 | Kramer Kelly A. | Director | Open Market Sale | -2.806 | 127,11 | -356.670,66 | -29,8% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2.476 | 126,26 | -312.613,57 | -26,1% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -25.524 | 125,83 | -3.211.559,85 | -268,1% | |
| 2025-11-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 125,23 | -313.075,00 | -26,1% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -35.965 | 122,30 | -4.398.591,43 | -367,2% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -17.181 | 124,00 | -2.130.444,00 | -177,9% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -500 | 122,90 | -61.452,00 | -5,1% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -7.978 | 119,54 | -953.666,98 | -79,6% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -2.022 | 118,82 | -240.258,69 | -20,1% | |
| 2025-10-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 118,08 | -354.240,00 | -29,6% | |
| 2025-10-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 118,08 | -295.200,00 | -24,6% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1.961 | 112,42 | -220.454,25 | -18,4% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -8.039 | 111,47 | -896.109,74 | -74,8% | |
| 2025-09-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3.000 | 113,57 | -340.710,00 | -28,4% | |
| 2025-09-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 113,57 | -283.925,00 | -23,7% | |
| 2025-08-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10.000 | 113,63 | -1.136.300,00 | -94,9% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2.800 | 118,51 | -331.820,72 | -27,7% | |
| 2025-08-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2.500 | 118,53 | -296.325,00 | -24,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11.800 | 118,51 | -1.398.405,02 | -116,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11.800 | 118,50 | -1.398.351,92 | -116,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -200 | 118,97 | -23.793,00 | -2,0% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -700 | 118,97 | -83.278,02 | -7,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 119.010.973 | 0 | 119.010.973 | 16.586.559.275 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 80.654.776 | 0 | 80.654.776 | 11.240.856.131 | Neu | +100,0% | |
| FMR LLC | 71.906.290 | 0 | 71.906.290 | 10.021.579.771 | Neu | +100,0% | |
| STATE STREET CORP | 59.858.585 | 0 | 59.858.585 | 8.342.490.991 | Neu | +100,0% | |
| Capital World Investors | 41.283.933 | 0 | 41.283.933 | 5.753.020.069 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 29.726.052 | 0 | 29.726.052 | 4.135.590.576 | Neu | +100,0% | |
| Capital Research Global Investors | 27.127.533 | 0 | 27.127.533 | 3.780.727.903 | Neu | +100,0% | |
| Invesco Ltd. | 26.054.487 | 0 | 26.054.487 | 3.631.213.853 | Neu | +100,0% | |
| DODGE & COX | 24.250.826 | 0 | 24.250.826 | 3.379.837.620 | Neu | +100,0% | |
| MORGAN STANLEY | 23.299.295 | 0 | 23.299.295 | 3.247.223.306 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 19.978.936 | 0 | 19.978.936 | 2.784.464.345 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 13.820.379 | 0 | 13.820.379 | 1.926.146.221 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 13.537.991 | 0 | 13.537.991 | 1.886.789.807 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 13.199.103 | 0 | 13.199.103 | 1.839.558.986 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 11.542.014 | 0 | 11.542.014 | 1.608.610.528 | Neu | +100,0% | |
| Amundi | 10.539.111 | 0 | 10.539.111 | 1.468.835.897 | Neu | +100,0% | |
| Legal & General Group Plc | 10.464.889 | 0 | 10.464.889 | 1.458.491.571 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8.181.780 | 0 | 8.181.780 | 1.140.294.679 | Neu | +100,0% | |
| Nuveen, LLC | 7.833.564 | 0 | 7.833.564 | 1.091.763.828 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 7.722.929 | 0 | 7.722.929 | 1.076.079.156 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 7.287.230 | 0 | 7.287.230 | 1.015.799.153 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 6.645.441 | 0 | 6.645.441 | 926.174.953 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 6.281.609 | 0 | 6.281.609 | 909.685.607 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 6.222.328 | 0 | 6.222.328 | 867.205.853 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 6.063.685 | 0 | 6.063.685 | 845.095.779 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 5.865.522 | 0 | 5.865.522 | 817.478.000 | Neu | +100,0% | |
| BARCLAYS PLC | 5.836.796 | 0 | 5.836.796 | 813.474.259 | Neu | +100,0% | |
| NORDEA INVESTMENT MANAGEMENT AB | 5.260.363 | 0 | 5.260.363 | 726.613.942 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 5.110.058 | 0 | 5.110.058 | 712.188.783 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 5.729.225 | 0 | 5.729.225 | 703.205.077 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 4.423.414 | 0 | 4.423.414 | 616.338.454 | Neu | +100,0% | |
| Boston Partners | 4.255.122 | 0 | 4.255.122 | 593.123.623 | Neu | +100,0% | |
| UBS Group AG | 4.144.104 | 0 | 4.144.104 | 577.563.774 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 3.978.823 | 0 | 3.978.823 | 554.528.634 | Neu | +100,0% | |
| Swiss National Bank | 3.641.000 | 0 | 3.641.000 | 507.446.170 | Neu | +100,0% | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 3.584.898 | 0 | 3.584.898 | 499.627.234 | Neu | +100,0% | |
| BANK OF MONTREAL /CAN/ | 3.549.224 | 0 | 3.549.224 | 494.655.264 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 3.484.026 | 0 | 3.484.026 | 485.568.473 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.447.111 | 0 | 3.447.111 | 480.424.000 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 3.372.079 | 0 | 3.372.079 | 469.966.650 | Neu | +100,0% | |
| HSBC HOLDINGS PLC | 3.231.139 | 0 | 3.231.139 | 449.718.508 | Neu | +100,0% | |
| Allianz Asset Management GmbH | 3.218.527 | 0 | 3.218.527 | 448.566.108 | Neu | +100,0% | |
| Robeco Institutional Asset Management B.V. | 3.459.893 | 3.354.394 | 105.499 | 437.122.881 | Aufgestockt | +3,1% | |
| FIRST TRUST ADVISORS LP | 3.129.637 | 0 | 3.129.637 | 436.177.491 | Neu | +100,0% | |
| VOYA INVESTMENT MANAGEMENT LLC | 3.052.813 | 0 | 3.052.813 | 425.470.599 | Neu | +100,0% | |
| National Pension Service | 3.021.468 | 0 | 3.021.468 | 421.101.995 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 2.931.232 | 0 | 2.931.232 | 408.525.804 | Neu | +100,0% | |
| Mitsubishi UFJ Asset Management Co., Ltd. | 2.922.953 | 0 | 2.922.953 | 407.371.960 | Neu | +100,0% | |
| Holocene Advisors, LP | 2.611.826 | 0 | 2.611.826 | 364.010.190 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 2.574.822 | 0 | 2.574.822 | 356.943.033 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Robeco Institutional Asset Management B.V. | 3.459.893 | 3.354.394 | +3,1% | 437.122.881 | 10,39 | 44 % | 17 Q |
| Assenagon Asset Management S.A. | 2.287.888 | 512.436 | +346,5% | 289.051.770 | 6,87 | 100 % | 17 Q |
| Swedbank AB | 1.903.177 | 2.398.000 | -20,6% | 240.447.384 | 5,71 | 100 % | 15 Q |
| Mirae Asset Global Investments Co., Ltd. | 926.242 | 835.044 | +10,9% | 117.021.414 | 2,78 | 100 % | 17 Q |
| Eurizon Capital SGR S.p.A. | 862.517 | 787.231 | +9,6% | 108.982.326 | 2,59 | 87 % | 3 Q |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | 832.632 | 861.023 | -3,3% | 105.194.766 | 2,50 | 100 % | 17 Q |
| Alecta Tjanstepension Omsesidigt | 814.325 | 814.325 | 0,0% | 102.824.818 | 2,44 | 100 % | 3 Q |
| Asset Management One Co., Ltd. | 720.732 | 735.649 | -2,0% | 91.057.281 | 2,16 | 100 % | 17 Q |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | 668.663 | 466.363 | +43,4% | 84.478.883 | 2,01 | 100 % | 16 Q |
| Crossmark Global Holdings, Inc. | 541.294 | 524.989 | +3,1% | 68.387.124 | 1,63 | 100 % | 17 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 603.836 | 489.770 | +23,3% | 65.312.945 | 1,55 | 4 % | 14 Q |
| Munich Reinsurance Co Stock Corp in Munich | 514.526 | 515.964 | -0,3% | 65.005.215 | 1,54 | 100 % | 4 Q |
| TD Waterhouse Canada Inc. | 482.201 | 552.773 | -12,8% | 60.789.121 | 1,44 | 100 % | 17 Q |
| ADAPT Investment Managers SA | 438.365 | 363.165 | +20,7% | 55.383.034 | 1,32 | 0 % | 2 Q |
| Erste Asset Management GmbH | 426.561 | 547.833 | -22,1% | 53.834.238 | 1,28 | 99 % | 17 Q |
| Resona Asset Management Co.,Ltd. | 400.627 | 422.586 | -5,2% | 50.614.428 | 1,20 | 100 % | 10 Q |
| Czech National Bank | 353.398 | 337.894 | +4,6% | 44.648.303 | 1,06 | 100 % | 16 Q |
| ATWOOD & PALMER INC | 350.240 | 347.439 | +0,8% | 44.249.360 | 1,05 | 100 % | 17 Q |
| MILLER WEALTH ADVISORS, LLC | 120.316 | 100 | +120216,0% | 42.511.252 | 1,01 | 0 % | 17 Q |
| IFM Investors Pty Ltd | 287.894 | 262.285 | +9,8% | 36.372.528 | 0,86 | 100 % | 17 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 845 | 36,5 | 4.218 |
| 31.03.2026 | ✓ | 2.278 | 1.171,5 | 155.468 |
| 31.12.2025 | ✓ | 2.175 | 1.147,0 | 133.489 |
| 30.09.2025 | ✓ | 2.016 | 1.121,7 | 119.706 |
| 30.06.2025 | ✓ | 1.994 | 1.090,4 | 113.234 |
| 31.03.2025 | ✓ | 1.973 | 1.095,9 | 116.250 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 80.654.776 | 11.240.856.131 |
| SEB Asset Management AB | 1.233.000 | 171.843.070 |
| Tredje AP-fonden | 359.230 | 50.065.886 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 329.337 | 45.899.698 |
| CIBC Bancorp USA Inc. | 318.021 | 44.321.152 |
| Empowered Funds, LLC | 195.463 | 27.241.678 |
| Fiera Capital Corp | 187.420 | 26.120.725 |
| NATIXIS | 156.715 | 21.841.370 |
| SteelPeak Wealth, LLC | 125.203 | 17.449.548 |
| Aware Super Pty Ltd as trustee of Aware Super | 118.590 | 16.527.888 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 71.906.290 | 6.326.800 | +9.6 % | 10.021.579.771 |
| GOLDMAN SACHS GROUP INC | 11.065.214 | 2.312.701 | +26.4 % | 1.542.158.912 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 6.281.609 | 2.058.305 | +48.7 % | 909.685.607 |
| Capital Research Global Investors | 27.127.533 | 1.820.462 | +7.2 % | 3.780.727.903 |
| FIRST TRUST ADVISORS LP | 3.129.637 | 1.683.586 | +116.4 % | 436.177.491 |
| Nuveen, LLC | 7.833.564 | 1.519.508 | +24.1 % | 1.091.763.828 |
| MARSHALL WACE, LLP | 2.310.515 | 1.517.130 | +191.2 % | 322.016.475 |
| Bellevue Group AG | 1.169.879 | 1.117.127 | +2117.7 % | 163.046.036 |
| OMERS ADMINISTRATION Corp | 1.163.062 | 1.088.354 | +1456.8 % | 162.095.951 |
| MILLENNIUM MANAGEMENT LLC | 1.180.760 | 1.044.841 | +768.7 % | 164.562.521 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| BlackRock, Inc. | 119.010.973 | -4.184.605 | -3.4 % | 16.586.559.275 |
| BARCLAYS PLC | 5.282.196 | -3.833.287 | -42.1 % | 736.179.657 |
| BANK OF AMERICA CORP /DE/ | 19.978.936 | -3.142.684 | -13.6 % | 2.784.464.345 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 73.460 | -3.095.415 | -97.7 % | 10.238.120 |
| Qube Research & Technologies Ltd | 121.052 | -2.425.986 | -95.2 % | 16.871.017 |
| WELLINGTON MANAGEMENT GROUP LLP | 13.537.991 | -2.369.313 | -14.9 % | 1.886.789.807 |
| Skandinaviska Enskilda Banken AB (publ) | 1.870 | -2.115.680 | -99.9 % | 260.524 |
| DODGE & COX | 24.250.826 | -2.032.685 | -7.7 % | 3.379.837.620 |
| FEDERATED HERMES, INC. | 797.709 | -1.831.827 | -69.7 % | 111.176.732 |
| Invesco Ltd. | 26.054.487 | -1.818.980 | -6.5 % | 3.631.213.853 |
Zusätzlich aktuell von 472 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 7,51 % | 93.327.127 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -8,97 pp | |
| 05.02.2026 | Abigail P. Johnson (+1) | Passiv (13G) | 5,30 % | 65.539.477 | Neu | |
| 13.05.2025 | Capital World Investors | Passiv (13G/A) | 4,30 % | 53.834.873 | -2,40 pp | |
| 24.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 8,20 % | 101.739.273 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 8,97 % | 111.820.711 | +0,04 pp | |
| 09.02.2024 | Capital World Investors | Passiv (13G/A) | 6,70 % | 83.698.215 | +1,20 pp | |
| 24.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 9,90 % | 122.790.297 | -0,60 pp | |
| 13.02.2023 | Capital World Investors | Passiv (13G) | 5,50 % | 68.900.998 | Neu | |
| 13.02.2023 | Capital Research Global Investors | Passiv (13G/A) | 4,40 % | 54.602.952 | -4,10 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 8,93 % | 112.038.324 | +0,50 pp | |
| 31.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 10,50 % | 131.555.769 | +0,40 pp | |
| 08.07.2022 | . BlackRock, Inc. | Passiv (13G) | 10,10 % | 126.932.693 | +0,60 pp | |
| 11.02.2022 | Capital Research Global Investors | Passiv (13G/A) | 8,50 % | 107.156.981 | -1,20 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,43 % | 105.803.799 | +0,23 pp | |
| 01.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 9,50 % | 118.961.206 | +0,60 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 06.05.2026 | Jared Moskowitz | – | House | Kauf | $1,001 – $15,000 |
| 06.05.2026 | Jared Moskowitz | – | House | Kauf | $1,001 – $15,000 |
| 27.03.2026 | Alan Armstrong | – | Senate | Kauf | $1,001 – $15,000 |
| 27.01.2026 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 23.09.2025 | Valerie Hoyle | – | House | Verkauf | $1,001 – $15,000 |
| 06.06.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 14.05.2025 | Josh Gottheimer | – | House | Verkauf | $1,001 – $15,000 |
| 12.05.2025 | Jefferson Shreve | – | House | Verkauf | $15,001 – $50,000 |
| 05.05.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 05.05.2025 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 16.04.2025 | John Boozman | – | Senate | Verkauf | $1,001 – $15,000 |
| 31.03.2025 | Jefferson Shreve | – | House | Kauf | $15,001 – $50,000 |
| 10.03.2025 | Carol Devine Miller | – | House | Kauf | $1,001 – $15,000 |
| 07.03.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 24.12.2024 | Marjorie Taylor Greene | – | House | Kauf | $1,001 – $15,000 |
| 29.10.2024 | Valerie Hoyle | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | 2.021.000.000 $ | 1,61 $ | 56.278.000.000 $ | 23.515.000.000 $ |
| 2025-12-31 | 10-K | – | 8.510.000.000 $ | 6,78 $ | 59.023.000.000 $ | 22.703.000.000 $ |
| 2025-09-30 | 10-Q | – | 3.052.000.000 $ | 2,43 $ | 58.533.000.000 $ | 21.540.000.000 $ |
| 2025-06-30 | 10-Q | – | 1.960.000.000 $ | 1,56 $ | 55.721.000.000 $ | 19.674.000.000 $ |
| 2025-03-31 | 10-Q | – | 1.315.000.000 $ | 1,04 $ | 56.434.000.000 $ | 19.162.000.000 $ |
| 2024-12-31 | 10-K | – | 480.000.000 $ | 0,38 $ | 58.995.000.000 $ | 19.330.000.000 $ |
| 2024-09-30 | 10-Q | – | 1.253.000.000 $ | 1,00 $ | 54.525.000.000 $ | 18.475.000.000 $ |
| 2024-06-30 | 10-Q | – | 1.614.000.000 $ | 1,29 $ | 53.579.000.000 $ | 18.281.000.000 $ |
| 2024-03-31 | 10-Q | – | -4.170.000.000 $ | -3,34 $ | 56.292.000.000 $ | 17.539.000.000 $ |
| 2023-12-31 | 10-K | – | 5.665.000.000 $ | 4,50 $ | 62.125.000.000 $ | 22.833.000.000 $ |
| 2023-09-30 | 10-Q | – | 2.180.000.000 $ | 1,73 $ | 62.373.000.000 $ | 22.314.000.000 $ |
| 2023-06-30 | 10-Q | – | 1.045.000.000 $ | 0,83 $ | 62.337.000.000 $ | 21.158.000.000 $ |
| 2023-03-31 | 10-Q | – | 1.010.000.000 $ | 0,80 $ | 61.876.000.000 $ | 20.997.000.000 $ |
| 2022-12-31 | 10-K | – | 4.592.000.000 $ | 3,64 $ | 63.171.000.000 $ | 21.240.000.000 $ |
| 2022-09-30 | 10-Q | – | 1.789.000.000 $ | 1,42 $ | 62.557.000.000 $ | 21.081.000.000 $ |
| 2022-06-30 | 10-Q | – | 1.144.000.000 $ | 0,91 $ | 62.870.000.000 $ | 20.236.000.000 $ |
| 2022-03-31 | 10-Q | – | 19.000.000 $ | 0,02 $ | 63.080.000.000 $ | 19.927.000.000 $ |
| 2021-12-31 | 10-K | – | 6.225.000.000 $ | 4,93 $ | 67.952.000.000 $ | 21.069.000.000 $ |
| 2021-09-30 | 10-Q | – | 2.592.000.000 $ | 2,05 $ | 67.098.000.000 $ | 21.470.000.000 $ |
| 2021-06-30 | 10-Q | – | 1.522.000.000 $ | 1,21 $ | 67.984.000.000 $ | 19.703.000.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 28,9 Mrd. | 28,6 Mrd. | 26,9 Mrd. | 27,0 Mrd. | 27,0 Mrd. | 98,2 % | +1,1% | |
| HIVProduct Sales | 20,8 Mrd. | 19,6 Mrd. | 18,2 Mrd. | 17,2 Mrd. | 16,3 Mrd. | 70,5 % | +5,8% | |
| HIVProducts Biktarvy | 14,3 Mrd. | 13,4 Mrd. | 11,9 Mrd. | 10,4 Mrd. | 8,6 Mrd. | 48,7 % | +6,8% | |
| Oncology Product | 3,2 Mrd. | 3,3 Mrd. | 2,9 Mrd. | – | – | 11,0 % | -1,6% | |
| Liver Disease | 3,2 Mrd. | 3,0 Mrd. | 2,8 Mrd. | – | – | 10,9 % | +6,5% | |
| HIVProducts Descovy | 2,8 Mrd. | 2,1 Mrd. | 2,0 Mrd. | 1,9 Mrd. | 1,7 Mrd. | 9,4 % | +30,5% | |
| Cell Therapy Products Total Cell Therapy Product Sales | 1,8 Mrd. | 2,0 Mrd. | 1,9 Mrd. | 1,5 Mrd. | 871,0 Mio. | 6,2 % | -6,8% | |
| HIVProducts Genvoya | 1,5 Mrd. | 1,8 Mrd. | 2,1 Mrd. | 2,4 Mrd. | 2,9 Mrd. | 5,1 % | -15,0% | |
| Other Products Yescarta | 1,5 Mrd. | 1,6 Mrd. | 1,5 Mrd. | 1,2 Mrd. | 695,0 Mio. | 5,1 % | -4,8% | |
| Trodelvy | 1,4 Mrd. | 1,3 Mrd. | 1,1 Mrd. | 680,0 Mio. | 380,0 Mio. | 4,7 % | +6,2% | |
| Liver Disease Products Sofosbuvir Velpatasvir | 1,3 Mrd. | 1,6 Mrd. | – | – | – | 4,3 % | -20,3% | |
| HIVProducts Odefsey | 1,2 Mrd. | 1,3 Mrd. | 1,4 Mrd. | 1,5 Mrd. | 1,6 Mrd. | 4,0 % | -9,4% | |
| Liver Disease Products Vemlidy | 1,1 Mrd. | 959,0 Mio. | – | – | – | 3,6 % | +11,6% | |
| Veklury | 911,0 Mio. | 1,8 Mrd. | 2,2 Mrd. | 3,9 Mrd. | 5,6 Mrd. | 3,1 % | -49,4% | |
| Liver Disease Products Other Liver Disease | 874,0 Mio. | 467,0 Mio. | – | – | – | 3,0 % | +87,2% | |
| Other Products Total Other Product Sales | 799,0 Mio. | 889,0 Mio. | 859,0 Mio. | 946,0 Mio. | 1,0 Mrd. | 2,7 % | -10,1% | |
| Royalty Contract And Other | 527,0 Mio. | 144,0 Mio. | 182,0 Mio. | 299,0 Mio. | 297,0 Mio. | 1,8 % | +266,0% | |
| Other Products Am Bisome | 509,0 Mio. | 533,0 Mio. | 492,0 Mio. | 497,0 Mio. | 540,0 Mio. | 1,7 % | -4,5% | |
| HIVProducts Other HIV | 500,0 Mio. | 434,0 Mio. | – | – | – | 1,7 % | +15,2% | |
| HIVProducts Symtuza Revenue Share | 495,0 Mio. | 592,0 Mio. | – | – | – | 1,7 % | -16,4% | |
| Cell Therapy Products Tecartus | 344,0 Mio. | 403,0 Mio. | 370,0 Mio. | 299,0 Mio. | 176,0 Mio. | 1,2 % | -14,6% | |
| Other Products Other | 290,0 Mio. | 356,0 Mio. | 225,0 Mio. | 253,0 Mio. | 209,0 Mio. | 1,0 % | -18,5% | |
| HCVProduct Sales | – | – | 1,8 Mrd. | 1,8 Mrd. | 1,9 Mrd. | – | – | |
| HCVProducts Sofosbuvir Velpatasvir | – | – | 1,5 Mrd. | 1,5 Mrd. | 1,5 Mrd. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product | – | – | 1,0 Mrd. | 988,0 Mio. | 969,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Vemlidy | – | – | 862,0 Mio. | 842,0 Mio. | 814,0 Mio. | – | – | |
| Products Revenue Share Symtuza | – | – | 529,0 Mio. | 530,0 Mio. | 531,0 Mio. | – | – | |
| Other HCV | – | – | 160,0 Mio. | 166,0 Mio. | 207,0 Mio. | – | – | |
| Other Products Letairis | – | – | 142,0 Mio. | 196,0 Mio. | 206,0 Mio. | – | – | |
| HIVProducts Complera Eviplera | – | – | 129,0 Mio. | 200,0 Mio. | 258,0 Mio. | – | – | |
| HIVProducts Truvada | – | – | 114,0 Mio. | 147,0 Mio. | 371,0 Mio. | – | – | |
| HIVProducts Stribild | – | – | 101,0 Mio. | 127,0 Mio. | 189,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Viread | – | – | 83,0 Mio. | 91,0 Mio. | 111,0 Mio. | – | – | |
| Hepatitis BVirus Hepatitis Delta Virus Product Other | – | – | 72,0 Mio. | 55,0 Mio. | 44,0 Mio. | – | – | |
| HCVProducts Ledipasvir Sofosbuvir | – | – | 70,0 Mio. | 115,0 Mio. | 212,0 Mio. | – | – | |
| Products Other HIV | – | – | 56,0 Mio. | 57,0 Mio. | 50,0 Mio. | – | – | |
| HIVProducts Atripla | – | – | – | – | 145,0 Mio. | – | – | |
| Other Products Zydelig | – | – | – | – | 62,0 Mio. | – | – | |
| Other Products Ranexa | – | – | – | – | 10,0 Mio. | – | – |
Quartalsverlauf
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Product | 7,3 Mrd. | 7,1 Mrd. | 6,6 Mrd. | 7,5 Mrd. | 6,9 Mrd. | 6,6 Mrd. | 94,5 % | -2,3% | |
| HIVProduct Sales | 5,3 Mrd. | 5,1 Mrd. | 4,6 Mrd. | 5,1 Mrd. | 4,7 Mrd. | 4,3 Mrd. | 67,9 % | +4,0% | |
| HIVProducts Biktarvy | 3,7 Mrd. | 3,5 Mrd. | 3,2 Mrd. | 3,5 Mrd. | 3,2 Mrd. | 2,9 Mrd. | 47,4 % | +6,2% | |
| Liver Disease | 819,0 Mio. | 795,0 Mio. | 758,0 Mio. | 733,0 Mio. | 832,0 Mio. | 737,0 Mio. | 10,5 % | +11,7% | |
| Oncology Product | 788,0 Mio. | 849,0 Mio. | 757,0 Mio. | 816,0 Mio. | 841,0 Mio. | 789,0 Mio. | 10,1 % | -3,4% | |
| HIVProducts Descovy | 701,0 Mio. | 653,0 Mio. | 586,0 Mio. | 586,0 Mio. | 485,0 Mio. | 426,0 Mio. | 9,0 % | +19,6% | |
| Cell Therapy Products Total Cell Therapy Product Sales | 432,0 Mio. | 485,0 Mio. | 464,0 Mio. | 485,0 Mio. | 521,0 Mio. | 480,0 Mio. | 5,6 % | -10,9% | |
| Royalty Contract And Other | 424,0 Mio. | 27,0 Mio. | 54,0 Mio. | 30,0 Mio. | 41,0 Mio. | 39,0 Mio. | 5,5 % | +1313,3% | |
| HIVProducts Genvoya | 377,0 Mio. | 377,0 Mio. | 364,0 Mio. | 449,0 Mio. | 440,0 Mio. | 403,0 Mio. | 4,9 % | -16,0% | |
| Trodelvy | 357,0 Mio. | 364,0 Mio. | 293,0 Mio. | 332,0 Mio. | 320,0 Mio. | 309,0 Mio. | 4,6 % | +7,5% | |
| Other Products Yescarta | 349,0 Mio. | 393,0 Mio. | 386,0 Mio. | – | – | – | 4,5 % | Neu | |
| Liver Disease Products Sofosbuvir Velpatasvir | 309,0 Mio. | 342,0 Mio. | 346,0 Mio. | 385,0 Mio. | 476,0 Mio. | 405,0 Mio. | 4,0 % | -19,7% | |
| Liver Disease Products Vemlidy | 280,0 Mio. | 252,0 Mio. | 252,0 Mio. | 232,0 Mio. | 243,0 Mio. | 225,0 Mio. | 3,6 % | +20,7% | |
| Veklury | 277,0 Mio. | 121,0 Mio. | 302,0 Mio. | 692,0 Mio. | 214,0 Mio. | 555,0 Mio. | 3,6 % | -60,0% | |
| HIVProducts Odefsey | 277,0 Mio. | 298,0 Mio. | 281,0 Mio. | 326,0 Mio. | 315,0 Mio. | 310,0 Mio. | 3,6 % | -15,0% | |
| Liver Disease Products Other Liver Disease | 231,0 Mio. | 201,0 Mio. | 161,0 Mio. | 116,0 Mio. | 113,0 Mio. | 107,0 Mio. | 3,0 % | +99,1% | |
| Other Products Total Other Product Sales | 184,0 Mio. | 202,0 Mio. | 209,0 Mio. | 201,0 Mio. | 280,0 Mio. | 224,0 Mio. | 2,4 % | -8,5% | |
| HIVProducts Symtuza Revenue Share | 124,0 Mio. | 124,0 Mio. | 114,0 Mio. | – | – | – | 1,6 % | Neu | |
| Other Products Am Bisome | 123,0 Mio. | 129,0 Mio. | 139,0 Mio. | 130,0 Mio. | 151,0 Mio. | 144,0 Mio. | 1,6 % | -5,4% | |
| HIVProducts Other HIV | 112,0 Mio. | 107,0 Mio. | 91,0 Mio. | 100,0 Mio. | 105,0 Mio. | 117,0 Mio. | 1,4 % | +12,0% | |
| Cell Therapy Products Tecartus | 83,0 Mio. | 92,0 Mio. | 78,0 Mio. | 98,0 Mio. | 107,0 Mio. | 100,0 Mio. | 1,1 % | -15,3% | |
| Other Products Other | 61,0 Mio. | 73,0 Mio. | 70,0 Mio. | 71,0 Mio. | 130,0 Mio. | 80,0 Mio. | 0,8 % | -14,1% | |
| Cell Therapy Products Yescarta | – | – | – | 387,0 Mio. | 414,0 Mio. | 380,0 Mio. | – | – | |
| HIVProducts Revenue Share Symtuza | – | – | – | 139,0 Mio. | 168,0 Mio. | 141,0 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 20,9 Mrd. | 20,6 Mrd. | 19,4 Mrd. | 18,9 Mrd. | 19,3 Mrd. | 70,9 % | +1,4% | |
| Europe | 5,1 Mrd. | 4,6 Mrd. | 4,3 Mrd. | 4,5 Mrd. | 4,9 Mrd. | 17,2 % | +9,3% | |
| Rest Of World | 3,5 Mrd. | 3,5 Mrd. | – | – | – | 11,9 % | -0,7% | |
| Other International | – | – | 3,4 Mrd. | 3,9 Mrd. | 3,2 Mrd. | – | – |
Quartalsverlauf
| Region | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|---|
| US | 5,3 Mrd. | 5,1 Mrd. | 4,7 Mrd. | 5,5 Mrd. | 4,9 Mrd. | 4,6 Mrd. | 68,0 % | -3,1% | |
| Europe | 1,6 Mrd. | 1,2 Mrd. | 1,1 Mrd. | 1,2 Mrd. | 1,1 Mrd. | 1,2 Mrd. | 20,0 % | +33,2% | |
| Rest Of World | 933,0 Mio. | 842,0 Mio. | 915,0 Mio. | 929,0 Mio. | 879,0 Mio. | – | 12,0 % | +0,4% | |
| Other International | – | – | – | – | – | 894,0 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | 7,0 Mrd. USD | 1,61 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 7,8 Mrd. USD | 2,43 |
| Q2 2025 | 30.06.2025 | 07.08.2025 | 7,1 Mrd. USD | 1,56 |
| Q1 2025 | 31.03.2025 | 07.05.2025 | 6,7 Mrd. USD | 1,04 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 7,5 Mrd. USD | 1,00 |
| Q2 2024 | 30.06.2024 | 08.08.2024 | 7,0 Mrd. USD | 1,29 |
| Q1 2024 | 31.03.2024 | 08.05.2024 | 6,7 Mrd. USD | -3,34 |
| Q3 2023 | 30.09.2023 | 07.11.2023 | 7,1 Mrd. USD | 1,73 |
| Q2 2023 | 30.06.2023 | 04.08.2023 | 6,6 Mrd. USD | 0,83 |
Dividenden
Dividende je Aktie (Jahr, SEC-XBRL)
| Jahr | DPS |
|---|---|
| 2025 | 3,1600 |
| 2024 | 3,0800 |
| 2023 | 3,0000 |
| 2022 | 2,9200 |
| 2021 | 2,8400 |
| 2020 | 2,7200 |
| 2019 | 2,5200 |
| 2018 | 2,2800 |
Beträge aus SEC-XBRL, Termine aus 8-K Item 8.01 (regelbasiert extrahiert, KI als Fallback), ohne Gewähr.
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | 31.03.2026 | 37 Tage | SEC » |
| 24.02.2026 | 10-K | 31.12.2025 | 55 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 08.05.2024 | 10-Q | 31.03.2024 | 38 Tage | SEC » |
| 23.02.2024 | 10-K | 31.12.2023 | 54 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 03.05.2023 | 10-Q | 31.03.2023 | 33 Tage | SEC » |
| 22.02.2023 | 10-K | 31.12.2022 | 53 Tage | SEC » |
| 02.11.2022 | 10-Q | 30.09.2022 | 33 Tage | SEC » |
| 08.08.2022 | 10-Q | 30.06.2022 | 39 Tage | SEC » |
| 04.05.2022 | 10-Q | 31.03.2022 | 34 Tage | SEC » |
| 23.02.2022 | 10-K | 31.12.2021 | 54 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 05.08.2021 | 10-Q | 30.06.2021 | 36 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.02.2021 | 10-K | 31.12.2020 | 56 Tage | SEC » |
| 04.11.2020 | 10-Q | 30.09.2020 | 35 Tage | SEC » |
| 06.08.2020 | 10-Q | 30.06.2020 | 37 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 18.05.2026 | Kapitalerhöhung | $3,00 Mrd | SEC » |
| 14.05.2026 | Kapitalerhöhung | – | SEC » |
| 15.11.2024 | Kapitalerhöhung | $3,50 Mrd | SEC » |
| 13.11.2024 | Kapitalerhöhung | – | SEC » |
| 11.09.2023 | Kapitalerhöhung | $1,98 Mrd | SEC » |
| 07.09.2023 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 20.03.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 20.03.2026 | HV-Einladung | — | — | DEF 14A | SEC » |
| 27.03.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.03.2025 | HV-Einladung | — | — | DEF 14A | SEC » |
| 28.03.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.03.2024 | HV-Einladung | — | — | DEF 14A | SEC » |
| 18.03.2024 | Vorläufig | — | — | PRE 14A | SEC » |
| 05.04.2023 | HV-Einladung | — | — | DEFR14A | SEC » |
| 23.03.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.03.2023 | HV-Einladung | 03.05.2023 Jahres-HV | 15.03.2023 | DEF 14A | SEC » |
| 24.03.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.03.2022 | HV-Einladung | 04.05.2022 Jahres-HV | 15.03.2022 | DEF 14A | SEC » |
| 30.03.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 30.03.2021 | HV-Einladung | 12.05.2021 Jahres-HV | 19.03.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 28.04.2026 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 17.04.2026 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 01.04.2026 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 06.03.2026 | Übernahmeangebot | SC TO-T | $115,00 Cash | SEC » |
| 23.02.2026 | Übernahmeangebot | SC TO-C | – | SEC » |
| 23.02.2026 | Übernahmeangebot | SC TO-C | – | SEC » |
| 22.03.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 20.03.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 15.03.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 11.03.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 28.02.2024 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 23.02.2024 | Übernahmeangebot | SC TO-T | $32,50 Cash · Frist 21.03.2024 | SEC » |
| 14.02.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
| 12.02.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
| 12.02.2024 | Übernahmeangebot | SC TO-C | – | SEC » |
| 23.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 14.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 13.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 02.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 19.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Section 13(a) of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 31.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.10.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 31.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 20.05.2026 | Finanzierung/Anleihe | 0,05 | 65 | Gilead Sciences gibt Schuldverschreibungen über eine Underwriting-Vereinbarung mit Barclays, BofA und Citigroup aus. Die Emission wird durch… 🔒 | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 55 | Gilead Sciences kündigte die Finanzergebnisse für Q1 2026 (zum 31. März 2026) an. Die Pressemitteilung mit Details zu GAAP- und Non-GAAP-Ken… 🔒 | SEC |
| 04.05.2026 | HV-Abstimmung | 0,00 | 25 | Die Jahreshauptversammlung von Gilead Sciences fand am 30. April 2026 mit einer Beteiligung von 1,13 Mrd. Aktien statt. Die Wahl der neun Vo… 🔒 | SEC |
| 28.04.2026 | M&A abgeschlossen | 0,20 | 70 | Gilead hat am 28. April 2026 die Übernahme von Arcellx erfolgreich abgeschlossen. | SEC |
| 23.02.2026 | M&A angekündigt | 0,40 | 75 | Gilead kündigt Merger mit Arcellx an. FDA akzeptiert BLA für anito-cel, ein BCMA-targeting CAR-T-Kandidat für multiple Myeloma. | SEC |
| 10.02.2026 | Quartalszahlen | 0,00 | 60 | Gilead veröffentlichte Q4 2025 und Jahresergebnisse 2025 nach GAAP und Non-GAAP-Standards. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-22 | 39 | 123,76 | 4.827 |
| 2026-06-12 | 2 | 125,87 | 252 |
| 2026-06-10 | 4 | 125,50 | 502 |
| 2026-06-08 | 4 | 129,16 | 517 |
| 2026-06-03 | 7.392 | 127,57 | 942.997 |
| 2026-05-19 | 915 | 129,67 | 118.648 |
| 2026-05-18 | 104 | 129,58 | 13.476 |
| 2026-05-12 | 7.252 | 133,52 | 968.287 |
| 2026-05-11 | 21.146 | 131,33 | 2.777.104 |
| 2026-05-08 | 13.968 | 134,06 | 1.872.550 |
| 2026-05-07 | 976 | 136,30 | 133.029 |
| 2026-05-04 | 6.552 | 131,65 | 862.571 |
| 2026-04-29 | 2 | 129,26 | 259 |
| 2026-04-24 | 3.148 | 133,64 | 420.699 |
| 2026-04-20 | 400 | 137,64 | 55.056 |
| 2026-04-17 | 4 | 138,55 | 554 |
| 2026-04-15 | 11 | 140,45 | 1.545 |
| 2026-04-14 | 690 | 139,03 | 95.931 |
| 2026-04-10 | 644 | 142,09 | 91.506 |
| 2026-04-08 | 5 | 138,80 | 694 |
| 2026-04-07 | 41 | 140,13 | 5.745 |
| 2026-04-06 | 9.676 | 139,71 | 1.351.834 |
| 2026-04-02 | 43 | 140,30 | 6.033 |
| 2026-03-30 | 1 | 134,25 | 134 |
| 2026-03-25 | 124 | 138,11 | 17.126 |
| 2026-03-19 | 1 | 141,29 | 141 |
| 2026-03-13 | 1.887 | 145,21 | 274.011 |
| 2026-03-11 | 31.755 | 148,56 | 4.717.523 |
| 2026-03-06 | 544 | 145,14 | 78.956 |
| 2026-03-04 | 4.937 | 147,83 | 729.837 |
| 2026-03-03 | 127 | 150,03 | 19.054 |
| 2026-02-23 | 130.529 | 151,40 | 19.762.091 |
| 2026-02-20 | 9.977 | 151,12 | 1.507.724 |
| 2026-02-19 | 61 | 152,74 | 9.317 |
| 2026-02-18 | 100 | 155,27 | 15.527 |
| 2026-02-06 | 25.326 | 149,37 | 3.782.945 |
| 2026-02-02 | 300 | 141,95 | 42.585 |
| 2026-01-30 | 224 | 139,55 | 31.259 |